Clinical Trials on Healthy Volunteers Type 2 Diabetes in Germany

Total 1155 results

Novo Nordisk A/S

Completed

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets

Type 2 Diabetes | Healthy Volunteers

Germany
AstraZeneca
Parexel

Completed

Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components

Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)

Germany
Novo Nordisk A/S

Completed

A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Germany, Denmark
Novo Nordisk A/S

Completed

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Novartis

Completed

Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

Healthy | Type-2 Diabetes

Germany
Eli Lilly and Company

Completed

A Single Dose Study of LY2605541 in Participants With Liver Impairment

Hepatic Insufficiency | Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany, Hungary
Eli Lilly and Company

Completed

A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes

Healthy | Type 2 Diabetes

Germany
Diamontech AG
Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft...

Recruiting

Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

Healthy | Diabetes Mellitus Type 2 | Diabetes Mellitus Type 1

Germany
Neuraly, Inc.

Completed

A Study With NLY01 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Type2 Diabetes

Germany
The Deutsche Diabetes Forschungsgesellschaft e.V.
Algiax Pharmaceuticals GmbH

Recruiting

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Type2 Diabetes

Germany
German Diabetes Center
Yale University

Enrolling by invitation

"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"

Type2 Diabetes

Germany
Charite University, Berlin, Germany
University Hospital Tuebingen; Technische Universität Berlin; German Institute...

Recruiting

Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins (MOCA)

NAFLD | Type2 Diabetes

Germany
Novo Nordisk A/S

Completed

A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Prof. Dr. Thomas Forst

Completed

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Type2 Diabetes Mellitus

Germany
Sanofi

Completed

A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes (ELDERLY-T)

Type 2 Diabetes Mellitus (T2DM)

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Diabetes | Type 2 Diabetes Mellitus

Germany
University of Erlangen-Nürnberg Medical School

Completed

Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

Type 2-diabetes

Germany
Novo Nordisk A/S

Completed

A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Germany
Munich Municipal Hospital
Novo Nordisk A/S

Unknown

Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Adocia

Completed

A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
West German Center of Diabetes and Health
Novartis Pharmaceuticals; Nintendo of Europe GmbH

Completed

Lifestyle Intervention With an Interactive Video Game for Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Germany
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
University Hospital Tuebingen

Withdrawn

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Type 2 Diabetes Mellitus (T2DM)

Germany
Novo Nordisk A/S

Completed

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Adocia

Completed

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
RWTH Aachen University
Boehringer Ingelheim

Completed

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes (EMPA)

Diabetes Mellitus Type 2 (T2DM)

Germany
Insuline Medical Ltd.

Completed

Testing the Effect of the InsuPad Device in Daily Life Conditions

Diabetes Mellitus Type 2 | Diabetics Mellitus Type 1

Germany
IKFE Institute for Clinical Research and Development

Completed

Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin (PIOswitch)

Type 2 Diabetes Mellitus | Insulin Resistance

Germany
Novartis

Completed

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Type 2 Diabetes Mellitus

Germany
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
Heinrich-Heine University, Duesseldorf

Recruiting

Mitochondrial Substrate Utilization in the Diabetic Human Heart

Heart Failure | Mitochondrial Diseases | Insulin Resistance | Diabetic Cardiomyopathies | Type2diabetes

Germany
German Diabetes Center
German Institute of Human Nutrition; Association of Statutory Health Insurance...

Completed

The Impact of a Diabetes Risk Prediction Model in Primary Care.

Type 2 Diabetes Mellitus | Primary Prevention

Germany
Cytos Biotechnology AG

Completed

Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany, Switzerland
Technische Universität Dresden

Completed

Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

Type 2 Diabetes | Overt Diabetic Nephropathy

Germany
RWTH Aachen University

Terminated

Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus (Diast Dysfkt)

Diabetes Mellitus Type 2 (T2DM) | Left Ventricular Diastolic Dysfunction

Germany
Dimini Konsortium
Deutsche Diabetes Gesellschaft

Unknown

DIMINI - Diabetes Mellitus? - Not me! (Dimini)

Diabetes Mellitus, Type 2 | Diabetes | Health Behavior | Health Knowledge, Attitudes, Practice | Literacy

Germany
University of Leipzig

Recruiting

Laboratory Study for the Acquisition of Spectral and Photoplethysmographic Data (LabStud_MSI)

Healthy Volunteers

Germany

3

Subscribe